Agilent Introduces New Cutting-Edge SureSelect DNA Kit
January 27 2020 - 2:00PM
Business Wire
Enhanced performance and flexibility to power cancer and
genetics research
Agilent Technologies Inc. (NYSE: A) today introduced a new
product designed to address key challenges that laboratories
encounter when preparing DNA sequencing libraries for their
research. The new Agilent SureSelect XT HS2 DNA Kit represents the
state-of-the-art in library preparation and target enrichment,
offering researchers a complete solution that allows them to choose
workflow options that best suit their needs.
Advantages of the new kit include:
- The ability to multiplex hundreds of samples in one sequencing
run, which reduces sequencing costs for high-throughput labs.
- The ability to remove sample contamination as a result of index
hopping from reads.
- Better error correction to detect variants with low allele
frequencies (particularly important in cancer applications where
the samples are often of varying tumor purity).
- The option to purchase Solid Phase Reversible Immobilization
(SPRI) beads and streptavidin beads as part of a complete kit.
“Agilent’s new SureSelect XT HS2 kit will help us accelerate our
capture-based enrichment library preparation, without sacrificing
quality,” said Zarko Manojlovic, Ph.D., assistant professor of
Research Translational Genomics, and director of the Keck Genomics
Platform (KGP). “Since most of our work is focused on the
processing of highly degraded samples, the integrated and modular
XT HS2 protocol truly provides us the flexibility to adjust on a
per-sample basis within a high-throughput processing integration.
This empowers us to create robust sample preparation pipelines to
push the boundaries of processing precious low-quantity and poor
quality samples in an integrated and efficient way.”
“The release of SureSelect XT HS2 demonstrates Agilent’s decade
long commitment to innovation of our SureSelect brand to ensure
that customers have access to the most comprehensive and
cutting-edge solutions for NGS library preparation,” said Lou
Welebob, vice president of Commercial Marketing, Diagnostics and
Genomics Group at Agilent. “We continue to evolve in order to
satisfy our customer’s unmet needs for cancer and constitutional
applications.”
Agilent is one of the only vendors in the industry to offer an
end-to-end solution for next-generation sequencing, including
sample quality control, library preparation, target enrichment,
automation, and data analysis.
KGP is a service platform designed to support the Keck School of
Medicine at the University of Southern California to provide
high-throughput, end-to-end next-generation sequencing services to
promote translation of the hidden secrets of genomics into
clinically relevant discovery and drive cutting-edge improvements
in human health.
About Agilent Technologies
Agilent Technologies Inc. (NYSE: A) is a global leader in life
sciences, diagnostics and applied chemical markets. Now in its 20th
year as an independent company delivering insight and innovation
toward improving the quality of life, Agilent instruments,
software, services, solutions, and people provide trusted answers
to customers' most challenging questions. The company generated
revenue of $5.16 billion in fiscal 2019 and employs 16,300 people
worldwide. Information about Agilent is available at
www.agilent.com. To receive the latest Agilent news, subscribe to
the Agilent Newsroom. Follow Agilent on LinkedIn, Twitter, and
Facebook.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20200127005614/en/
Naomi Goumillout Agilent Technologies +1.781.266.2819
naomi.goumillout@agilent.com
Agilent Technologies (NYSE:A)
Historical Stock Chart
From Mar 2024 to Apr 2024
Agilent Technologies (NYSE:A)
Historical Stock Chart
From Apr 2023 to Apr 2024